Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: Effect on plasma homocysteine

Nephron

Volumn 89, Issue 3, 2001, Pages 297-302

  De Vecchi, Amedeo F ^a,c   Patrosso, Cristina ^b   Novembrino, Cristina ^a   Finazzi, Silvia ^a   Colucci, Patrizia ^a   De Franceschi, Michela ^a   Fasano, Maria Antonietta ^a   Bamonti Catena, Fabrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Erythrocyte folate; Folate supplementation; Folate therapy; Homocysteine; Peritoneal dialysis; Serum folate; Vitamin B12

Indexed keywords

AMINO ACID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; REDUCTION; SIGNAL DETECTION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANOREXIA; DEPRESSION; DOWN-REGULATION; ERYTHROCYTES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; SLEEP INITIATION AND MAINTENANCE DISORDERS; VITAMIN B 12;

EID: 0035742836     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046089     Document Type: Article

References (23)

1. Homocysteine and heart disease in dialysis patients
2. Homocysteine and atherothrombosis
3. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
4. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
5. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
6. Folate supplementation in the dialysis patients - Fragmentary evidence and tentative recommendations
7. Folic acid treatment of hyperhomocysteinemia in dialysis patients
8. 12, serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients
9. Toxicity of folic acid given in pharmacological doses to healthy volunteers
10. Folate measurements in patients on regular hemodialysis treatment
11. Whole blood folate concentrations: Comparison between Stratus Folate (DADE) and radioassay (DPC) methods
12. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
13. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy
14. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
15. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
16. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
17. High-dose B vitamin treatment of homocysteinemia in dialysis patients
18. Effect of usual doses of folate supplementation on elevated plasma homocysteine in hemodialysis patients. No difference between 1 and 5 mg daily
19. Major determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis patients
20. Mutation (667C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
21. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
22. Folic acid safety and toxicity - A brief review
23. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients. No change in endothelial function after long-term therapy